Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

-current portion of equipment

financing 1,352,684 955,695

Deferred rent and other non-current

liabilities 1,576,734 1,464,902

Total liabilities 11,851,683 12,472,671

Commitments

Stockholders' equity:

Common stock 3,437 2,944

Additional paid-in capital 320,579,240 298,073,896

Deferred stock-based compensation (251,601) (1,006,604)

Accumulated other comprehensive

income (loss) 69,262 (21,376)

Accumulated deficit (279,006,083) (240,245,163)

Total stockholders' equity 41,394,255 56,803,697

Total liabilities and stockholders'

equity $53,245,938 $69,276,368

Note 1: The condensed balance sheet at December 31, 2006 has been

derived from the audited financial statements at that date

included in the Company's Form 10-K for the fiscal year ended

December 31, 2006.

SUNESIS PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended Twelve months ended

December 31, December 31,

2007 2006 2007 2006

Revenue:

Collaboration

revenue $37,500 $229,167 $1,576,610 $6,353,585

Collaboration

revenue from

related party 1,759,208 1,725,810 7,586,903 7,317,700

License revenue 250,000 - 500,000 -

Grant and

fellowship

revenue
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... in PLoS Medicine , Susan Huang and colleagues ... tool, WHONET-SaTScan, made by integrating two freely available software ... software to microbiology data from patients admitted to a ... years (2002-2006), the authors found that the tool identified ...
... ... for fermenters is projected to reach $180 million by the year 2015. Growth in the ... disposable or single-use fermenters. , ... San Jose, California (PRWEB) February 22, 2010 -- Fermenters are witnessing sizeable growth in demand, ...
... in a special ink infused with nanoparticles, Stanford engineer ... efficiently manufacture lightweight paper batteries and supercapacitors (which, like ... means), as well as stretchable, conductive textiles known as ... mechanical properties of ordinary paper or fabric. While ...
Cached Biology Technology:Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 2Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 3Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 4US Fermenters Market to Reach $180 million by 2015, According to New Report by Global Industry Analysts, Inc. 2US Fermenters Market to Reach $180 million by 2015, According to New Report by Global Industry Analysts, Inc. 3Nanotechnology sparks energy storage on paper and cloth 2Nanotechnology sparks energy storage on paper and cloth 3
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... Polar Regions and the deep sea is the focus ... involving over 200 international scientists. The CAREX (Coordination ... roadmap outlines priorities for future research into life in ... Life has evolved thousands of strategies to adapt and ...
... nearly 390,000 chemical compounds had led scientists to a ... the brain with effects promising for new drugs for ... which blocks formation of cholesterol in the brain, in ... G. Kazantsev and colleagues previously discovered that blocking cholesterol ...
... lifted off on board India,s Polar Satellite Launch Vehicle ... on 20 April 2011. The X-SAT, developed ... collaboration with DSO National Laboratories, was launched from the ... India. The wholly made-in-Singapore satellite was one ...
Cached Biology News:Life in extreme environments paves the way for international collaboration 2Singapore's first locally made satellite launched into space 2
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
KRIT1 Immunogen: KRIT1 (NP_004903, 637 a.a. ~ 737 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: